Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays

Transfusion

Volumn 42, Issue 11, 2002, Pages 1507-1513

  Galel, Susan A ^a,b,c,d,e   Strong, D Michael ^a,b,c,d,e   Tegtmeier, Gary E ^a,b,c,d,e   Holland, Paul V ^a,b,c,d,e   Kuramoto, Isamu K ^a,b,c,d,e   Kemper, Marti ^a,b,c,d,e   Pietrelli, Larry ^a,b,c,d,e   Gallarda, James ^a,b,c,d,e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

^c Division of New York Blood Center Enterprises   (United States)

^d Center for Blood Research   (United States)

^e ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; BLOOD; BLOOD DONOR; CLINICAL TRIAL; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MASS SCREENING; METHODOLOGY; MULTICENTER STUDY; PREDICTION AND FORECASTING; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TIME; UNITED STATES; VIREMIA; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; BLOOD DONORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES; TIME FACTORS; UNITED STATES; VIREMIA;

EID: 0036831812     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2002.00236.x     Document Type: Article

References (22)

1. 1 Francis B, Taboada F, Andiorio E, et al. Demonstration of improved sensitivity and specificity in blood donors by a prototype HCV 3.0 ELISA. Transfusion 1993 ; 33 (Suppl.): 32S.
2. 2 Sun R, Jayakar H, Yeh S, et al. Experience with PCR screening. Dev Biol Stand 2000 ; 102: 81 ‐ 91.
3. 3 Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993 ; 74: 1093 ‐ 102.
4. 4 Vernelen K, Claeys H, Verhaert H, et al. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994 ; 343: 853.
5. 5 Goffin E, Pirson Y, Cornu C, et al. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994 ; 343: 854.
6. 6 Barrera JM, Francis B, Ercilla G, et al. Improved detection of anti‐HCV in post‐transfusion hepatitis by a third‐ generation ELISA. Vox Sang 1995 ; 68: 15 ‐ 8.
7. 7 Courouce AM, Le Marrec N, Girault A, et al. Anti‐hepatitis C virus (anti‐HCV) seroconversion in patients undergoing hemodialysis: comparison of second‐ and third‐generation anti‐HCV assays. Transfusion 1994 ; 34: 790 ‐ 5.
8. 8 Psichogiou M, Katsoulidou A, Vaindirli E, et al. Immunologic events during the incubation period of hepatitis C virus infection: the role of antibodies to E2 glycoprotein. Multicentre Hemodialysis Cohort Study on Viral Hepatitis. Transfusion 1997 ; 37: 858 ‐ 62.
9. 9 Vrielink H, Reesink HW, Van Den Burg PJ, et al. Performance of three generations of anti‐hepatitis C virus enzyme‐linked immunosorbent assays in donors and patients. Transfusion 1997 ; 37: 845 ‐ 9.
10. 10 Lee SR, Wood CL, Lane MJ, et al. Increased detection of hepatitis C virus infection in commercial plasma donors by a third‐generation screening assay. Transfusion 1995 ; 35: 845 ‐ 9.
11. 11 Dow BC, Follett EA, Davidson F, et al. Comparison of second‐ and third‐generation hepatitis C virus enzyme‐linked immunosorbent assays in a low risk blood donor population. Transfusion 1996 ; 36: 477 ‐ 8.
12. 12 Tobler LH, Lee SR, Stramer SL, et al. Performance of second‐ and third‐generation RIBAs for confirmation of third‐generation HCV EIA‐reactive blood donations. Retrovirus Epidemiology Donor Study. Transfusion 2000 ; 40: 917 ‐ 23.
13. 13 Hitzler WE, Runkel S. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV. Transfusion 2001 ; 41: 333 ‐ 7.
14. 14 Committee report. Nucleic acid amplification testing of blood donors for transfusion‐transmitted infectious diseases: report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000 ; 40: 143 ‐ 59.
15. 15 Courouce AM, Noel L, Barin F, et al. A comparative evaluation of the sensitivity of five anti‐hepatitis C virus immunoblot assays. Vox Sang 1998 ; 74: 217 ‐ 24.
16. 16 De Medina M, Hill M, Sullivan HO, et al. Detection of anti‐hepatitis C virus antibodies in patients undergoing dialysis by utilizing a hepatitis C virus 3.0 assay: correlation with hepatitis C virus RNA. J Lab Clin Med 1998 ; 132: 73 ‐ 5.
17. 17 Dow BC, Buchanan I, Munro H, et al. Relevance of RIBA‐3 supplementary test to HCV PCR positivity and genotypes for HCV confirmation of blood donors. J Med Virol 1996 ; 49: 132 ‐ 6.
18. 18 Galan F, Perez‐Gracia MT, Lozano A, et al. A 3‐year follow‐up of HCV‐RNA viraemia in haemodialysis patients. Nephrol Dial Transplant 1998 ; 13: 1211 ‐ 4.
19. 19 Umlauft F, Gruenewald K, Weiss G, et al. Patterns of hepatitis C viremia in patients receiving hemodialysis. Am J Gastroenterol 1997 ; 92: 73 ‐ 8.
20. 20 Arase Y, Ikeda K, Chayama K, et al. Fluctuation patterns of HCV‐RNA serum level in patients with chronic hepatitis C. J Gastroenterol 2000 ; 35: 221 ‐ 5.
21. 21 Kuramoto IK, Moriya T, Schoening V, Holland PV. Fluctuation of serum HCV‐RNA levels in untreated blood donors with chronic hepatitis C virus infection. J Viral Hepat 2002 ; 9: 36 ‐ 42.
22. 22 Notari EP, Orton SL, Cable RG, et al. Seroprevalence of known and putative hepatitis markers in United States blood donors with ALT levels at least 120 IU per L. Transfusion 2001 ; 41: 751 ‐ 5.